Site Search

Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance

Investment will support discovery research of a novel Gene Coding^TM approach that could benefit all people with CF regardless of their mutation
 

Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations.

Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.

White will be the first person living with CF to lead the Board into a new era of CF

New funding will support clinical development of two novel therapies to address complications of cystic fibrosis

Early stage researchers, life science entrepreneurs, and companies are encouraged to apply starting May 2

New modulators in development by the CF-specific company could provide unique treatment options for the underlying cause of cystic fibrosis for many people with the disease

Carbon Biosciences is the first company to publicly launch from the Foundation’s collaboration with Longwood Fund and the first to work alongside CF Foundation researchers at the Foundation’s therapeutics lab